Assessing Quality of Life in Patients Undergoing Allogeneic Stem Cell Transplantation
the Cancer Therapy Advisor take:
Health-related quality of life (HRQL) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) was linked to whether the transplant was after myeloablative conditioning (MAC) or reduced intensity conditioning (RIC), according to an article posted online in the European Journal of Cancer Care.
Participants included 94 patients who were undergoing HSCT after MAC (n = 18) or RIC (n= 76). The EORTC QLQ C-30 was used to assess HRQL in patients during the inpatient period and throughout the following 3 years.
Patients’ functional status and global quality of life (eg, role,social functions) were observed to have decreased from baseline to weeks 2 and 3.
Symptoms including appetite loss, nausea and vomiting, diarrhea and fatigue significantly increased during the first 3 weeks.
HRQL took at least 1 year to return to baseline level, but only role function was found to have significantly improved 3 years post-transplantation.
Patients who initially received MAC had a significantly worse HRQL at baseline, along with patients with extensive chronic graft-versus-host disease. Patients who received MAC also experienced more pain, interrupted sleep, and appetite loss in weeks 3 and 4 compared to those who received RIC.
Quality of life linked to whether the transplant was after myeloablative conditioning or reduced intensity conditioning.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed